Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
M.de WildeM
Why it did so well: Victoza, a prominent GLP-1 agonist from Novo Nordisk, secured substantial sales, amounting to $1.796 billion in 2022, although experiencing an 18 percent decline
Patients with renal impairment, elderly individuals, and those taking multiple glucose-lowering medications face higher risk of severe complications
Due to this effect, there has been a concern regarding the risk of intestinal obstruction with the use of GLP-1RAs
US$ 25.99
US$ 27.91
US$ 22.03
US$ 24.59
US$ 26.83
US$ 26.24
US$ 21.95
US$ 21.62
US$ 27.89
US$ 29.36
US$ 23.39
US$ 24.76
US$ 26.22
US$ 22.65
